Semaglutide and the cost of CV benefit
A 2026 cost-effectiveness review places semaglutide, a GLP-1 agonist, in the moderate tier for preventing cardiovascular events. Here is what that means.
Why we wrote this. Readers meet semaglutide through weight-loss headlines. A cost-effectiveness review reframes it as cardiovascular prevention with a price tag worth understanding.
In this article (4 sections)
A June 2026 cost-effectiveness review in the American Journal of Therapeutics sorted 13 cardiovascular drugs into three price tiers, and it placed semaglutide in the middle tier rather than the cheap one[1]. The drug works on hard cardiovascular outcomes. It is just not the most economical way to prevent a heart attack, and that gap is the whole point of the paper.
The review is a narrative read of 19 cardiovascular outcomes trials and the European and American guidelines built on them, with no formal meta-analysis applied[1]. It is not a new trial, and it does not change what semaglutide does in the body. What it adds is a price lens on a drug that many readers first meet through weight-loss coverage rather than through a health-system budget.
Where semaglutide landed
The authors grouped the 13 agents by incremental cost-effectiveness ratio, which is the extra spend needed to buy one extra quality-adjusted life year (one year of life in full health, the standard health-economics unit). Generic drugs such as ramipril, carvedilol, metformin and generic statins sat in the low-cost tier, under 20,000 dollars per quality-adjusted life year. Semaglutide and the older GLP-1 agonist liraglutide sat in the moderate tier, roughly 3,000 to 50,000 dollars. The PCSK9 inhibitors evolocumab and alirocumab sat in the high-cost tier, 80,000 to 300,000 dollars[1].
The review also reported a number-needed-to-treat for each drug, meaning how many patients you have to treat to prevent one event. Semaglutide came in at 43 and liraglutide at 51[1]. For comparison the generic agents ran far lower, with metformin between 9 and 15. A lower number is better, because fewer treated patients buy each prevented event.
Why the cardiovascular benefit is real
The price tier is a judgement about value, not about whether the drug works. The cardiovascular signal behind semaglutide is among the strongest for any peptide we cover. In the SELECT trial, adults with overweight or obesity and established cardiovascular disease but no diabetes had a 20 percent lower rate of major adverse cardiovascular events on semaglutide 2.4 mg, with a primary event in 6.5 percent of the drug group versus 8.0 percent on placebo (hazard ratio 0.80, P<0.001)[2]. Major adverse cardiovascular events here means the combined count of cardiovascular death, non-fatal heart attack and non-fatal stroke. SELECT was the first time a weight-loss medicine showed a hard cardiovascular benefit in people who did not have diabetes, which is why the result carried so far beyond the obesity field.
That trial is why semaglutide now appears in any serious conversation about preventing cardiovascular morbidity, the broad term for heart and vascular disease that the cost-effectiveness review opens with. The review frames the stakes plainly: cardiovascular disease caused 19.8 million deaths in 2022, about 32 percent of deaths worldwide[1].
What this is not
Not a regulator downgrade. The European Medicines Agency authorises Wegovy, the higher-dose semaglutide brand, for weight management in adults with obesity or with overweight plus a weight-related condition such as cardiovascular disease[3]. The label lists cardiovascular disease as a qualifying condition, and it does not carry a standalone European indication for cutting cardiovascular events. A price tier in a journal review and a regulator indication are two different things, and neither one is a treatment recommendation.
Not a verdict against the drug either. A moderate cost-effectiveness ratio still means the spending buys real benefit, which is more than can be said for the high-cost tier in the same paper. The honest reading is narrower: when a cheap generic delivers a similar outcome, a health system weighing a fixed budget will reach for the generic first, and an expensive newer drug has to clear a higher bar.
Where this lands for readers
If you are reading about semaglutide for the heart rather than the scale, two facts travel together. The benefit is well evidenced, and the price keeps it out of the cheapest tier of cardiovascular prevention. For how the drug is classified and reimbursed where you live, see the per-country detail on the semaglutide regulation pages and the wider regulation hub, and read the underlying trial and review documents in the sources below before drawing any conclusion of your own.
Frequently asked
Does semaglutide actually reduce cardiovascular events?
Yes, in one large trial. SELECT (Lincoff et al., NEJM 2023) reported a 20 percent reduction in major adverse cardiovascular events (hazard ratio 0.80, P<0.001) in adults with overweight or obesity and established cardiovascular disease but no diabetes, on semaglutide 2.4 mg weekly. The cost-effectiveness review does not dispute that benefit; it ranks the drug on price.
Why is semaglutide only in the moderate cost tier?
Because cheaper generic drugs deliver similar mortality benefits at a lower number-needed-to-treat. The review placed generics such as ramipril, carvedilol, metformin and generic statins below 20,000 dollars per quality-adjusted life year, while semaglutide and liraglutide fell in the 3,000 to 50,000 dollar moderate band. The benefit is real; the value per dollar is lower than for the generics.
What does number-needed-to-treat of 43 mean?
It means roughly 43 patients have to be treated with semaglutide for one of them to avoid a cardiovascular event, in the review's analysis. Liraglutide came in at 51 and metformin between 9 and 15. A lower number is better, because fewer treated patients are needed to buy each prevented event.
Is this paper telling doctors to stop prescribing semaglutide?
No. It is a narrative cost-effectiveness review, not a guideline or a prescribing instruction. It describes where each drug sits on value for money so health systems can plan budgets. Decisions about any individual prescription belong with a clinician who knows the patient.
Sources
- [1]Leah et al. (2026): Repurposed Drugs and Cardiovascular Morbidity, A Cost-Effectiveness Analysis (Am J Ther; PMID 42340212)Tier 1 · primary↩
- [2]SELECT trial: Lincoff et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (NEJM, 2023; PMID 37952131)Tier 1 · primary↩
- [3]Wegovy (semaglutide): EMA EPAR (centrally authorised, prescription-only)Tier 1 · primary↩
No revisions yet. First published .